HARLIKU

The single-dose pharmacokinetics of nitisinone tablets have been studied in healthy adult subjects. Nitisinone pharmacokinetic parameters are presented as geometric mean [range] unless otherwise specified. Nitisinone maximum concentration (Cmax) and area under the curve from time 0 to 120 hours (AUC0-120h) were 1278 [780 to 1649] ng/mL and 77874 [42335 to 104211] ng

• h/mL following oral administration of 10 mg (5 times the recommended dosage) nitisinone under fasting conditions.

AbsorptionNitisi...

The effectiveness of HARLIKU was evaluated in an open-label, single center, randomized, no-treatment controlled trial in 40 adult patients diagnosed with AKU ( NCT00107783 ). Patients received either HARLIKU at 2 mg orally once daily or no treatment for three years. One patient in the HARLIKU group died after experiencing atrial fibrillation and had discontinued treatment one month prior to death, and 2 patients in the no treatment control group discontinued the study early. Among the 40 patients enrolled in the trial, 27 (67.5%) were male and 13 (32.5%) were female, ranging in age from 38 to ...

Most common adverse reactions (>1%) are elevated tyrosine levels, keratitis and thrombocytopenia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Cycle Pharmaceuticals Ltd at 1-855-831-5413 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Serious and/or clinically significant adverse reactions described elsewhere in labeling include: Ocular Symptoms and Hyperkeratotic Plaques Due to Elevated Plasma Tyrosine Levels [see Warnings and Precautions ( 5.1 )] Leukopenia and Severe Thrombocytope...

None. None. ( 4 )

Ocular Symptoms and Hyperkeratotic Plaques Due To Elevated Plasma Tyrosine Levels : Inadequate restriction of tyrosine and phenylalanine intake can lead to elevations in plasma tyrosine and levels above 500 micromol/L may lead to ocular signs and symptoms or painful hyperkeratotic plaques on the soles and palms. ( 5.1 ) Assess plasma tyrosine levels in patients presenting with ocular signs and symptoms. ( 5.1 ) Obtain slit-lamp examination prior to treatment and regularly thereafter. ( 5.1 ) Imp...

7 DRUG INTERACTIONS Sensitive CYP2C9 Substrates: Reduce dosage of co-administered drug metabolized by CYP2C9 by half. ( 7.1 ) OAT1/OAT3 Substrates : Avoid concomitant use of HARLIKU with OAT1/OAT3 substrates. Concomitant use with OAT1/OAT3 substrates may increase the risk of adverse reactions related to the co-administered drug. ( 7.1 ) 7.1 Effects of HARLIKU on Other Drugs Sensitive CYP2C9 Substr...